Animal agriculture plays a pivotal role in the spread and development of antimicrobial resistance (AMR). Animal pharmaceutical companies are uniquely positioned to either drive responsible antibiotic use practices or contribute to the development and spread of AMR. This engagement tackles the lack of transparency from animal pharmaceutical companies over how they manufacture, market, and sell antibiotics – practices that could contribute to AMR hotspots developing in the environment and driving high levels of unnecessary antibiotic use. It aims to encourage seven of the world’s largest publicly listed animal pharmaceutical companies to recognise the material risk posed by AMR and to improve disclosures around their approach to antibiotic stewardship, including AMR mitigation efforts.

Target companies:

• Dechra
• Elanco
• MSD
• Phibro
• Vetoquinol
• Virbac
• Zoetis

Please see the attached engagement letter template for more details.

Engagement contact: Sophie Bartley, ESG Analyst, [email protected]